enrolled, 78 with reported INH resistance and 20 with INH intolerance. BIW dosing was used in 77 and TIW in 21. Study treatment was completed in 73 (74%). Reasons for discontinuation were hepatic adverse events (n ¼ 12), other adverse effects (n ¼ 3) and other reasons (n ¼ 10). Failure (n ¼ 1) and relapse (n ¼ 2) occurred in 3 (3.5%, 95%CI 1.2-9.8) of 86 patients eligible for efficacy analysis, all occurring in patients with cavitary, acid-fast bacilli smear-positive pulmonary TB. C O N C L U S I O N S : Intermittent RMPþPZAþEMB appears to be effective in HIV-negative patients, but the regimen is poorly tolerated, possibly due to the prolonged use of PZA. Alternative regimens of lower toxicity are needed. K E Y W O R D S : tuberculosis; anti-tuberculosis agents; mycobacterial infections ISONIAZID (INH), a key component of anti-tuberculosis treatment, 1 may not be used due to INH drug resistance, INH intolerance or toxicity, or when INH is unavailable. 2, 3 For drug-susceptible TB, a 6-month regimen of INH, rifampin (RMP) and pyrazinamide (PZA) during an intensive 2-month period, followed by INH and RMP for the 4-month continuation phase, has been shown to be highly effective whether administered daily or on an intermittent twice-or thrice-weekly schedule. Intermittent regimens including ethambutol (EMB) or streptomycin (SM) for the first 8 weeks facilitate the use of directly observed therapy, [4] [5] [6] which in turn markedly improves adherence to and outcomes of anti-tuberculosis treatment. 7 The 1993 US Public Health Service recommendations for anti-tuberculosis treatment in the United States that were operative at the time of this study included two options for the treatment of patients with TB due to INH-resistant strains (detected in .4% of previously untreated TB cases in the United States 8 ) and those with INH-induced hepatitis, occurring in 4% of individuals on anti-tuberculosis treatment. 9 These options were a 12-month regimen of RMPþEMB and a 6-month regimen of RMPþEMBþPZA; 10 the latter was supported by data from 12 randomized studies of 6-month regimens, many administered thrice-weekly, demonstrating efficacy despite baseline INH resistance as long as RMP resistance was absent. 11 We report the findings of a study evaluating the hypothesis that a 6-month directly observed regimen of RMPþPZAþEMB would be effective, safe and tolerable when given twice or thrice weekly.
METHODS
The Tuberculosis Trials Consortium conducted a prospective, open-label, single-arm study from 5 August 1999 to 27 October 2004. The primary outcome measure was the combined rate of failure during treatment and relapse after treatment completion. The secondary outcome measures were tolerability and safety. Institutional review boards at both the US Centers for Disease Control and Prevention (CDC) and participating sites approved the protocol.
Human immunodeficiency virus (HIV) negative adults aged 718 years with culture-confirmed tuberculosis (TB) and a clinical decision not to use INH within the first 70 days of treatment were enrolled. Documentation of an adequate initial regimen was required, based on the then-current 1993 US guidelines, 10 with the specific requirement that RMP, PZA and EMB (or SM) be used along with INH until resistance or intolerance to INH was detected. Exclusion criteria included resistance or intolerance to RMP, PZA or EMB, .21 days of antituberculosis treatment with other drugs with known tuberculosis activity, pregnancy, diagnosis of silicotuberculosis or TB of the central nervous system, amino aspartate transaminase (AST) .3 times the upper limit of normal (ULN), and total bilirubin level .2.5 3 ULN.
Study treatment
After pre-enrollment treatment of 14-70 days, study treatment consisting of intermittent, directly observed RMPþEMBþPZA was started, preferably twice weekly, although thrice weekly was permitted. Medications followed the then-current guidelines for twiceweekly weekly dosing: 10 RMP 600 mg, EMB 40-50 mg/kg and PZA 40-70 mg/kg. Participants changing from twice to thrice weekly to manage intolerance were assigned the following recommended dosing: RMP 600 mg, EMB 25-35 mg/kg, and PZA 30-40 mg/kg. Completion of treatment was defined initially as receiving 26 weeks of RMPþEMBþPZA within 32 calendar weeks, and was later extended to 38 weeks within 44 calendar weeks for participants who had both cavitary lung disease and positive sputum cultures after 2 months of treatment. 1 
Study procedures
The study divided participant involvement into treatment (combining pre-study and study treatment) and follow-up (Figures 1 and 2) . During study treatment, participants were evaluated monthly for toxicity. Sputum specimens were collected monthly from participants with pulmonary TB until two negative cultures were obtained, at the first three post-treatment visits, at 24 months, and when relapse was suspected.
Baseline Mycobacterium tuberculosis isolates and isolates obtained on suspicion of treatment failure or relapse were sent to the CDC mycobacteriology laboratory for identification and drug susceptibility testing (DST), when available. An independent adjudication committee evaluated all participants with positive cultures occurring after early discontinuation or after 16 weeks of treatment, and reviewed clinical information and DNA profiling of relevant isolates to confirm endpoints. Treatment failure was suspected for a positive TB culture following 16 calendar weeks of treatment, and relapse was suspected for a positive TB culture within 2 years of treatment completion.
Adverse events were reported to the data center by the site investigators. They were defined as hepatic at the discretion of site investigators or were identified as hepatic if the AST or alanine aminotransferase (ALT) value was .5 x ULN or if the AST or ALT value was .3 x ULN in the presence of symptoms consistent with hepatitis.
Sample size and statistical considerations
A sample size of 215 participants would allow the study to distinguish a failure and relapse rate of 710% from the historically acceptable rate of 5% (range 4-6), with a one-sided comparison of proportions, 95% confidence, 80% power and up to 30% loss to follow-up.
To assess risk factors for failure and relapse and for hepatic events, we used the Wilson score method 12 to construct confidence intervals (CIs) for proportions and exact logistic regression to quantify strength of association. All calculations were carried out in SAS 9.2 (SAS Institute, Cary, NC, USA) and R 2.14.0 (R Development Core Team, Vienna, Austria). Probabilities of developing hepatic events were calculated with time-to-event analysis using the Kaplan-Meier method. 13 
RESULTS

Enrollment and baseline characteristics
The trial enrolled 98 participants between August 1999 and October 2004, including 78 with reported resistance and 20 with INH intolerance; 89% had pulmonary TB, with or without additional extrapulmonary disease, and 48% had evidence of cavitary disease on chest radiograph ( Table 1) . Because of slow accrual, enrollment was stopped early after consultation with the data monitoring committee. Interim analysis indicated that data on participants enrolled by the time of stopping would be sufficient to support the primary hypothesis. 14 All participants were included in tolerability and safety analyses. The assessment of successful treatment, characterized by the lack of treatment failure and relapse, uses the data from 86 participants, with 76 months of follow-up after treatment.
Enrollment was based on a site report of INH resistance in 78 (80%) participants; subsequent tests found 6 of these to be INH-susceptible, leaving confirmed resistance in 72 (73%). CDC mycobacteriol evaluation of enrollment isolates from 41 participants detected resistance to one or more other drugs besides INH (Table 1) ; none had resistance to RMP. One patient with INH susceptibility at the CDC discontinued study treatment and one with PZA resistance stopped study treatment due to hepatitis. Treatment lasted up to 9 months, and follow-up lasted up to 2 years. All patients were evaluated for safety and tolerability, including patients found to be ineligible for efficacy analysis. Two participants experienced relapse after 11 and 26 months of follow-up, and were considered to have completed post-treatment follow-up. All six deaths occurred after completion of study treatment; four were attributed to cancer, one to cocaine toxicity and one to complications following surgery for multiple decubitus ulcers after an incapacitating cardiac event. Treatment patterns and adverse events Pre-study treatment lasted a median of 55 days (range 13-73) before the start of study treatment using INH until resistance or intolerance was detected, along with the required regimen of RMPþEMBþPZA in all but four, who received SM instead of EMB during pre-study treatment. Pre-study treatment for one participant was administered thrice weekly, but the remainder received at least 14 daily directly observed therapy (DOT) doses, followed by twice-weekly or thrice-weekly dosing. The focus on early implementation of intermittent dosing resulted in a median number of 39 observed doses (range 23-70, interquartile range 33-54) during the first 70 days of combined pre-study and study anti-tuberculosis treatment. Among all participants, 74% completed the RMPþEMBþPZA study treatment regimen, while the remaining 26% did not complete the prescribed regimen, none due to death ( Figure 1 and Table 1 ). The most common reasons for incomplete treatment were adverse drug events (n ¼ 15) and non-adherence (n ¼ 5). Among the 15 participants who permanently discontinued study treatment because of adverse events ( Figure 2 , Table 2 ), reasons included hepatic events (n ¼ 12), nausea (n ¼ 1), rash (n ¼ 1) and flulike symptoms (n ¼ 1). None experienced renal impairment.
Physicians started thrice-weekly regimens for 16 participants (median PZA dose 33 mg/kg, range 29-43) and twice-weekly for 82 (median PZA dose 51 mg/kg, range 33-60), of whom 7 were changed to thrice-weekly to manage drug intolerance. Treatment was completed by 14/16 compared to 59/82 participants started on thrice-weekly and twice-weekly dosing, respectively. Of the five who changed to thrice-weekly dosing due to gastro-intestinal complaints, two completed study treatment, while three discontinued due to hepatic adverse events.
Twelve participants (12.2%, 95%CI 7.1-20.2) ( Table 2 ) discontinued treatment due to hepatotoxicity. None of these had bilirubin elevations or other consequences of severe liver injury such as hospitalization or death. PZA was permanently discontinued for all 12: seven were presumed to have PZA intolerance as they tolerated the resumption of offstudy regimens that included RMP and EMB (three had recurrent hepatic transaminase enzyme elevations with PZA rechallenge), two completed treatment with EMB and levofloxacin (one of whom failed an RMP re-challenge); two who had events occurring after completing 144 and 168 days of anti-tuberculosis treatment did not resume any treatment, and one was lost to follow-up. There were no significant associations of plausible risk factors with hepatic adverse events ( Table 3) . The median enrollment twice-weekly PZA dose among patients discontinuing due to hepatic events was 51 mg/kg (range 42-54), very similar to enrollment doses administered to participants who did not experience treatment-limiting hepatic events (median 51, range 33-60). Probabilities for developing hepatic events from start of anti-tuberculosis treatment were as follows: days 0-84, 1%; 85-112, 5%, 113-140, 2%; 141-168, 2%; and 169-196, 2%.
Treatment failures and relapses
Overall, 87% of participants completed 76 months of follow-up after treatment ( Figure 1, Table 1 ). Persons who completed study treatment were more likely than those not completing treatment to complete 76 months of follow-up (OR 7.4, P , 0.01), but only seven (7.1%) patients were lost to follow-up during the treatment phase (Figure 2) .
The adjudication committee reviewed data for six participants who had a positive culture result either after the last study dose or 16 weeks (112 days) after starting anti-tuberculosis treatment, and concluded that 1 participant experienced treatment failure ( Figure 2 , participant 20), 2 relapsed (participants 23 and 26) and 3 were determined not to have failure or relapse ( Figure 2 ). Among the 86 participants with 76 months of follow-up, the combined failure/relapse rate was thus 3.5% (95%CI 1.2-9.8), excluding with 95% confidence the possibility that the true combined rate was 710%. None of the three patients with treatment failure or relapse had follow-up isolates showing acquired drug resistance, and all three were successfully treated with alternative regimens. None of the participants with poor outcomes had treatment interruptions before their event, but all three participants started the study regimen on twice-weekly treatment, were aged 745 years, had acid-fast bacilli smear-positive sputum and cavitary pulmonary TB (OR 5.1, P ¼ 0.08). Of the 15 (20%) patients with all of these features, three experienced treatment failure or relapse, compared to 0/71 (0%) patients lacking all of these features ( Table 4) . The absence or level of INH resistance did not influence the incidence of treatment-limiting adverse events, hepatic events or treatment failure and relapse (data not shown).
DISCUSSION
The study results suggest that the intermittent, directly observed regimen of RMPþEMBþPZA had acceptable efficacy in HIV-negative patients with TB who are unable to receive INH due to resistance or intolerance. Similar outcomes were reported among 2682 patients treated in the 1970s and 1980s using 4-or 5-drug 6-month DOT regimens (largely thriceweekly) for pulmonary TB, when INH resistance was identified in isolates from 230 patients. 11 Failures occurred in under 1%, and relapses occurred in 15 (6.5%) and 94 (4.0%) of those with and without resistance to INH, respectively. 11 More recent US retrospective studies found relapse rates of 5% and 2%. 15, 16 Comparable results were observed in the 1980s among 226 patients treated in Kenya with 2 months of RMPþEMBþPZA plus SM, followed by either 4 or 7 months of RMPþEMB given supervised on a daily basis rather than intermittently. 17 This study has several limitations. We recruited only 45% of the planned sample size of patients before stopping due to slow enrollment. Patient accruals were on target early on when patients with 18, 19 Unfortunately, enrollment dropped dramatically when this became a stand-alone consortium-wide study. CIs were therefore wider than expected, although the upper limit was still below 10%. This study was not large enough to detect a modest risk for acquired resistance to RMP, 19 or the association of baseline cavitation with treatment failure and relapse. 18 The study included patients with INH intolerance as well as with INH-resistant isolates identified from local rather than reference laboratory results. A number of participants with discordant laboratory results continued in the study due to delays in obtaining the CDC reference laboratory results. Poor treatment outcomes were not associated with category of resistance vs. INH intolerance or with discordance in DST results between local and CDC laboratories. The latter finding is consistent with known intra-laboratory variability for EMB and PZA. 20 This multicenter prospective study provides valuable information in addition to a number of singlesite, retrospective studies published in the last decade, 15, 16, [21] [22] [23] some of which reported acquired RMP resistance, particularly when DOT was not used 21 or treatment was inadequate for the initial 2-5 months. 23 Reflecting the paucity of new information, the only significant change in the US 2003 treatment guidelines for patients with INH-resistant TB was to 'consider adding' a fluoroquinolone to RMP, EMB and PZA for patients with extensive TB disease. 1 A Kenyan study, 17 however, supported the 2006 UK National Institute for Health and Clinical Excellence guidelines to treat INH-resistant TB with 9-12 months of daily RMPþEMB, depending upon whether PZAþSM or PZA alone were co-administered during the first 2 months. 24 While the present study supports confidence in the efficacy of the currently recommended 6-month regimen of 6 months of RMP, EMB and PZA when INH cannot be used, it also raises concerns about tolerability. Study treatment was discontinued in 26% of participants, including 12% for hepatic events that were often attributed to PZA. Although not comparatively evaluated in this study, twiceweekly RMPþEMBþPZA appeared to be poorly tolerated, possibly due to the prolonged administration of the higher doses that World Health Organization (WHO) guidelines recommend for intermittent use of PZA, 25 the drug most strongly associated with liver injury in standard four-drug anti-tuberculosis regimens. 15, 21, 22, 26 The study did not provide data to explore why PZA toxicity might be more prevalent in the absence of concurrent INH treatment. 27 Despite issues of tolerability, PZA is receiving increasing attention due to its importance in anti-tuberculosis treatment. 28, 29 A recent systematic review reported treatment failure rates of 18-44% when patients with INHresistant TB were treated with the standardized WHO 8-month re-treatment regimen that includes INHþRMPþEMB for the final 6 months. This showed some evidence of benefit from prolonged PZA use, and the authors recommended further studies of regimens for INH-resistant TB. 30 The potential risk of acquired resistance to other secondor third-line drugs such as fluoroquinolones 31 also supports the need for further studies to identify better regimens for patients unable to receive INH. . Las razones aducidas de la interrupción fueron los efectos adversos hepá ticos (n ¼ 12), otras reacciones adversas (n ¼ 3) y causas diferentes (n ¼ 10). Se presentó un fracaso terapéutico y dos recaídas (n ¼ 3) (3,5%; IC95% 1,2-9,8) en los 86 pacientes aptos para el aná lisis de eficacia y estos casos ocurrieron en pacientes con TB pulmonar, baciloscopia positiva y cavernas en el parénquima pulmonar. C O N C L U S I Ó N: Un régimen intermitente con RMP, PZA y EMB parece ser eficaz en los pacientes sin infección por el VIH, pero se observa una baja tolerabilidad, tal vez debida al uso prolongado de PZA. Se precisan nuevas opciones terapéuticas que presenten una menor toxicidad.
